DUBLIN–(BUSINESS WIRE)–The “Hay Fever Conjunctivitis – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. This “Hay Fever Conjunctivitis- Market Insights, Epidemiology, and Market Forec…
Author: Business Wire
Outlook on the Military Protective Eye-Wear Global Market to 2028 – Emergence of Laser Protection Eye-wear Presents Opportunities – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Military Protective Eye-Wear Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type and End User” report has been added to ResearchAndMarkets.com’s offering. The military protective eyewear market was valued…
Warby Parker to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 17, 2022
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and fiscal year 2021 will be released before ma…
EyeSouth Partners Affiliates With Gadsden Eye Associates, Representing the Network’s 29th Affiliation and Second in Alabama
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed an affiliation with Gadsden Eye Associates, Vision Alabama and the Northeast Alabama Eye Surgery Center. The affiliation represents E…
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announces the initiation of a Phase 3 trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of active TED.
NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the engagement of one of China’s leading…
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for AMP-100, …
Italian Patients Receive Samsara Vision’s SING IMT™, a New Technology for Age-Related Macular Degeneration
FAR HILLS, N.J.–(BUSINESS WIRE)– #AMD–Italian Patients Receive Samsara Vision’s SING IMT™, a New Technology for Age-Related Macular Degeneration.
I primi 3 pazienti italiani ricevono il SING IMT™ di Samsara Vision, una nuova tecnologia per la degenerazione maculare legata all'età
FAR HILLS, N.J.–(BUSINESS WIRE)–Samsara Vision, un’azienda focalizzata nel restituire la vista e l’autonomia a pazienti affetti da degenerazione maculare senile (AMD) all’ultimo stadio attraverso dispositivi protesici visivi avanzati, ha annunciato o…
EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies
LONDON & NEW YORK–(BUSINESS WIRE)–Eyebiotech Limited (EyeBio), a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A…
Jeito Capital co-dirige un financement de série A pour EyeBio de 65 millions de dollars (57 millions d’euros)
PARIS–(BUSINESS WIRE)–Jeito Capital co-dirige un financement de série A pour EyeBio de 65 millions de dollars (57 millions d’euros).
United States Fiber Optic Collimating Lens Industry to 2027 – Rapidly Increasing Vet Care Spending Across the U.S. Presents Opportunities – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Fiber Optic Collimating Lens Market Research Report by Mode, by Type, by Lens Type, by Wavelength, by Application, by State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to Researc…
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
DURHAM, N.C.–(BUSINESS WIRE)–AERI 4Q & FY21 Save-the-Date
Introducing the EyeQue MyReaderNumber App: Personalized Results for Reading and Computer Glasses
NEWARK, Calif.–(BUSINESS WIRE)– #futureisnow–Today EyeQue®, the leader in at-home vision testing, introduced a first-of-its-kind smartphone app called MyReaderNumber™ that offers AR technology vision testing for presbyopia, a common age-related visi…
Iveric Bio to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022.
Samenvatting: Het Zwitserse Eye Research Institute heeft een baanbrekend casusrapport gepubliceerd met behulp van blootstelling aan licht en nutraceuticals voor de behandeling van retinale degeneratie
LUGANO, Zwitserland–(BUSINESS WIRE)–Dr. Roberto Pinelli, CEO van het Switzerland Eye Research Institute, kondigde vandaag de publicatie aan van een baanbrekend artikel in Archives Italiennes de Biologie, een van de oudste tijdschriften voor neurowete…
Resumen: El Switzerland Eye Research Institute ha publicado un informe sobre un caso innovador en el que se utiliza la exposición a la luz y los nutracéuticos para tratar la degeneración de la retina
LUGANO, Suiza–(BUSINESS WIRE)–El Dr. Roberto Pinelli, CEO del Switzerland Eye Research Institute, el instituto suizo de investigación ocular, ha anunciado hoy la publicación de un artículo innovador en Archives Italiennes de Biologie, una de las revi…
LO SWITZERLAND EYE RESEARCH INSTITUTE HA PUBBLICATO UN SENSAZIONALE CASO CLINICO CHE COMBINA L’ESPOSIZIONE ALLA LUCE E I NUTRACEUTICI NEL TRATTAMENTO DELLA DEGENERAZIONE RETINICA
LUGANO, Svizzera–(BUSINESS WIRE)–Il Dr. Roberto Pinelli, CEO dello Switzerland Eye Research Institute, ha annunciato oggi la pubblicazione di un articolo rivoluzionario nella rivista Archives Italiennes de Biologie, una delle più antiche riviste scie…